March 25 (Reuters) - Emergent BioSolutions Inc said the U.S. Food and Drug Administration approved its treatment for inhaled anthrax, triggering a $7 million milestone payment from the U.S. Department of Health and Human Services.

The treatment, Anthrasil, is a sterile solution of purified human immune globulin G (IgG) that targets the anthrax toxins of Bacillus anthracis, the bacteria that causes anthrax disease.

(Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings)